MedTrace Logo

A Phase I Study to Evaluate LSALT Peptide

NCT03772678 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2024-11-29

Study results available
· View outcomes & findings →

Summary

A phase I double-blind, placebo-controlled, randomized, single and multiple ascending dose finding study to evaluate the safety and pharmacokinetic profile of LSALT peptide in healthy participants

Conditions

  • None - Study is to Determine Safety in Healthy Participants

Interventions

DRUG

LSALT peptide

novel 16 amino acid peptide

OTHER

0.9% Saline

saline

Sponsors & Collaborators

  • Arch Biopartners Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-27
Primary Completion
2020-03-31
Completion
2020-03-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03772678 on ClinicalTrials.gov